Casgevy™ (exagamglogene autotemcel) and Lyfgenia® (lovotibeglogene autotemcel) – New orphan drug approvals
December 8, 2023 - The FDA announced the approval of two gene therapies for sickle cell disease (SCD): Vertex’s Casgevy (exagamglogene autotemcel) and bluebird bio’s Lyfgenia (lovotibeglogene autotemcel).
Top